LOGIN  |  REGISTER
Cue Biopharma

UNITY Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference

February 28, 2023 | Last Trade: US$0.10 0.00 0.00

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 9:50 AM ET.

The webcast of the presentation will be accessible here and through the “Investors and Media” section of our website, www.unitybiotechnology.com, under “Events & Presentations.”

About UNITY

UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact
Evoke Canale
Katherine Smith
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page